COMPASS Pathways

CMPS · Nasdaq · United Kingdom

Share price · CMPS

$8.12-5.78 (-41.58%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.4M (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CMPS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 2 Nov 2026-27.3%
  2. 9 Sep 2026+8.0%
  3. 5 Aug 2026+15.1%
  4. 13 May 2026+17.0%
  5. 20 Apr 2026+42.0%

    Nothing announced by CMPS that day or the session before.

  6. 16 Apr 2026+11.7%

    Nothing announced by CMPS that day or the session before.

  7. 17 Feb 2026+31.3%
  8. 4 Dec 2025+11.6%

    Nothing announced by CMPS that day or the session before.

Share of unusual movement by asset

For each asset, the share of CMPS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Psilocybin (COMP360) (COMP360)
events and moves
6shown from 8 days
Assets with fewer than 8 event days, together—23%
Other company news (earnings, financing, releases naming no asset)—18%
Sessions with no dated event—58%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
5-HT2A receptorSmall molecule
Major Depressive DisorderPost-Traumatic Stress Disorder

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
November 2028 (1)
Psilocybin (COMP360)Phase 2/3PTSD - Post Traumatic Stress Disorder, PTSD, PTSD Symptoms, PTSD, Post Traumatic Stress Disorder
Est. primary completion 2028-11 · NCT07570654 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

5 August 2026Filing submittedPsilocybin (COMP360)Rolling NDA submission for COMP360 in treatment-resistant depression underway
US, FDA · Source ↗
17 February 2026Topline resultPsilocybin (COMP360)COMP006 Phase 3 meets primary endpoint
Compass Pathways · Source ↗
23 June 2025Topline resultPsilocybin (COMP360)COMP005 Phase 3 meets primary endpoint
Compass Pathways · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$23M$444M$9.8M-$51M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$29M$434M$254M-$40M operating cash flowreport ↗
2026-Q1—$26M$466M—-$48M operating cash flowreport ↗
2025-Q3—$27M$186M$138M-$35M operating cash flowreport ↗
2025-Q2—$30M$222M$38M-$39M operating cash flowreport ↗
2025-Q1—$31M$260M$18M-$46M operating cash flowreport ↗
2024-Q3—$33M$207M$39M-$22M operating cash flowreport ↗
2024-Q2—$29M$229M$38M-$34M operating cash flowreport ↗
2024-Q1—$25M$263M$35M-$21M operating cash flowreport ↗
2023-Q3—$22M$248M$33M-$17M operating cash flowreport ↗
2023-Q2—$20M$148M$28M-$25M operating cash flowreport ↗
2023-Q1—$19M$117M$24M-$28M operating cash flowreport ↗
2022-Q3—$14M$173M$18M-$19M operating cash flowreport ↗
2022-Q2—$16M$207M$21M-$18M operating cash flowreport ↗
2022-Q1—$15M$244M$21M-$23M operating cash flowreport ↗
2021-Q3—$12M$294M$16M-$14M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$118M$150M$72M-$157M operating cash flowreport ↗

Revenue was not disclosed. R&D spend was $118.44M, down 0.5% YoY, and cash and equivalents were $149.99M. The company reported a net loss of $287.86M, with a quarterly net burn of $287.86M.

The company expects its cash position at March 24, 2026 to fund operations into 2028. It plans to meet with the FDA to confirm a rolling NDA submission for COMP360 in treatment-resistant depression, expects to complete the NDA submission in Q4, and anticipates 26-week Part B data from COMP006 in early Q3 2026. A Phase 2b/3 PTSD trial is initiating after FDA acceptance of the IND, commercial readiness is being advanced for launch by the end of 2026, and a $150M February financing plus $200M warrant exercise extended the cash runway.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$119M$165M$39M-$119M operating cash flowreport ↗
2023-FY—$88M$221M$30M-$97M operating cash flowreport ↗
2022-FY—$65M$143M$23M-$105M operating cash flowreport ↗
2021-FY—$44M$273M$18M-$68M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-03Nath Kabir · director, Chief Executive OfficerTax withholding5,962$11.25$67KForm 4
2026-05-27Tregoning Kathleen · directorAward / grant (derivative)41,119——Form 4
2026-05-27Norton David Y · directorAward / grant (derivative)21,110——Form 4
2026-05-27McQuade Robert · directorAward / grant (derivative)21,110——Form 4
2026-05-27Riley Wayne Joseph · directorAward / grant (derivative)21,110——Form 4
2026-05-27JONAS JEFFREY M · directorAward / grant (derivative)21,110——Form 4
2026-05-27Gover Justin D. · directorAward / grant (derivative)21,110——Form 4
2026-05-27SANTINI GINO · directorAward / grant (derivative)30,158——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 190 reporting institutions held 93.3M shares ($514.8M, 69.2% of shares outstanding).

#InstitutionSharesValue
1Deep Track Capital, LP12,161,496$67.3M
2RTW INVESTMENTS, LP10,632,390$58.8M
3MARSHALL WACE, LLP4,038,335$22.3M
4TANG CAPITAL MANAGEMENT LLC4,002,200$22.1M
5BIT Capital GmbH3,491,234$19.3M
6ARK Investment Management LLC3,301,050$18.3M
7MILLENNIUM MANAGEMENT LLC3,138,522$17.4M
8GMT Capital Corp3,078,536$17.0M
9TWO SIGMA INVESTMENTS, LP2,583,499$14.3M
10DAFNA Capital Management LLC2,418,882$13.4M
11BAKER BROS. ADVISORS LP2,344,720$13.0M
12Eagle Health Investments LP2,060,427$11.4M
13NEXTBio Capital Management LP2,021,407$11.2M
14UBS Group AG1,855,070$10.3M
15Kalehua Capital Management LLC1,639,384$9.1M